DBV Technologies (NASDAQ:DBVT) Shares Up 6.2% - Here's Why

Key Points

• DBV Technologies shares rose 6.2% to about $14.89 in midday trading, though trading volume was 85% below the stock’s average daily volume.
• Analyst sentiment remains mixed but leans positive: MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $48.50, despite recent downgrades to “sell.”
• The company reported a significant quarterly loss, with EPS of -$0.60 versus a consensus estimate of -$0.12, while revenue of $0.70 million also fell short of expectations.

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) shot up 6.2% during mid-day trading on Monday . The company traded as high as $14.77 and last traded at $14.8850. 45,287 shares traded hands during mid-day trading, a decline of 85% from the average daily volume of 304,978 shares. The stock had previously closed at $14.02.

Analysts Set New Price Targets

DBVT has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Citigroup restated an "outperform" rating on shares of DBV Technologies in a research note on Friday, May 1st. Wall Street Zen lowered DBV Technologies from a "hold" rating to a "sell" rating in a report on Saturday, July 4th. Weiss Ratings downgraded DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 17th. Finally, Guggenheim reiterated a "buy" rating and set a $51.00 price target on shares of DBV Technologies in a report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $48.50.

DBV Technologies Price Performance

The stock has a market capitalization of $930.00 million, a PE ratio of -4.21 and a beta of -0.93. The stock's 50 day simple moving average is $15.21 and its two-hundred day simple moving average is $18.70.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last released its earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.48). DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%. The company had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.90 million. As a group, equities research analysts predict that DBV Technologies S.A. will post -2.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

Institutional investors and hedge funds have recently bought and sold shares of the company. Allworth Financial LP bought a new stake in shares of DBV Technologies in the fourth quarter valued at $32,000. Royal Bank of Canada purchased a new position in shares of DBV Technologies during the 4th quarter valued at $34,000. Truvestments Capital LLC grew its stake in shares of DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company's stock worth $75,000 after acquiring an additional 1,620 shares during the period. Persistent Asset Partners Ltd bought a new position in shares of DBV Technologies during the 4th quarter worth $115,000. Finally, Two Sigma Investments LP purchased a new stake in DBV Technologies in the 3rd quarter worth about $167,000. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source